Description

Technical Parameters

Dostinex 0.25mg 100 tablets/bottle Core Information *

Pharmaceutical -grade tablets | Cabergoline (dopamine receptor agonist )

Chemical name : 1-[(6-allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea

CAS number : 81409-90-7

Molecular formula : C₂₆H₃₇N₅O₂

Molecular weight : 451.61

Specifications : 0.25 mg/tablet, 100 tablets/bottle

Appearance : White tablet

Core Effects

Cabergoline (Dostinex) is a long-acting dopamine receptor agonist . Due to its potent prolactin-inhibiting properties and excellent tolerability , it is widely used in the treatment of hyperprolactinemia, Parkinson's disease, and the prevention of progestin-related side effects during steroid cycles .

✅ Potent prolactin suppression :

Selectively activates D2 dopamine receptors and inhibits prolactin secretion from the anterior pituitary

Rapidly reduce serum prolactin levels , effective within 24 hours

✅ Prevention of progesterone-related side effects :

Blocking progesterone receptors to prevent progesterone side effects during steroid cycles

Reduce the risk of feminization and effectively control breast tissue hyperplasia

✅ High tolerance advantage :

The half-life is as long as 63-69 hours , and it can be taken once or twice a week.

Fewer gastrointestinal side effects and significantly better tolerance than bromocriptine

✅ Advantages :

Low dosing frequency and high patient compliance

Strong specificity , does not affect the secretion of other pituitary hormones

End Product Preparation Guidelines

1. Tablet preparation (0.25 mg/tablet) :

Example recipe (for 1000 tablets):

Cabergoline raw material: 0.25g

Microcrystalline cellulose: 80.0g

Lactose: 50.0g

Cross-linked carboxymethyl cellulose sodium: 8.0g

Magnesium stearate: 2.0g

Preparation process :

Raw material pretreatment : micronization (D90≤10μm)

Equal amount incremental mixing : gradually mix with diluent

Wet granulation : granulate with appropriate amount of purified water and dry in fluid bed at 50°C

Granulation : 20 mesh sieve granules, add flow aids and lubricants

Tableting : 6mm round die, 8-10kN pressure tableting

Film coating : Gastro-soluble film coating to improve stability and palatability

Quality Control :

Content uniformity : RSD≤3% (UV-HPLC detection)

Dissolution rate : ≥85% in 30 minutes (paddle method, 50 rpm)

Related substances : Single impurity ≤ 0.5%, total impurities ≤ 1.0%

2. Preparation Notes :

Raw material characteristics : Ergoline derivative, highly photosensitivity

Production environment : relative humidity ≤ 40%, avoid light operation

Packaging requirements : Aluminum foil blister packaging, light-proof and moisture-proof

Cycle Protocol

1. Treatment of Hyperprolactinemia :

Starting dose : 0.25 mg twice a week

Maintenance dose : 0.5-1.0 mg/week, divided into 1-2 doses

duration : Long-term, adjusted according to prolactin levels

2. Prevention of progestogen side effects :

Dosage : 0.25-0.5 mg twice a week

Cycle : Used in conjunction with a steroid cycle

Effect : Effectively prevent progesterone-related estrogen-induced breast cancer

3. Parkinson's disease treatment :

Starting dose : 0.5 mg/day, divided into two doses

Maximum dose : no more than 3.0 mg/day

Treatment course : Long-term treatment with regular evaluation of efficacy

4. Dosage adjustment guidelines :

Starting dose : 0.25 mg twice a week

Incremental adjustment : increase by 0.25 mg/time every 4 weeks

Maximum dose : no more than 1.0 mg/time, twice a week

Lifecycle Support and Management

In- use monitoring :

Prolactin level monitoring :

Test once a month after starting treatment

Once target levels are reached, test every 3-6 months

Heart Valve Monitoring :

Long-term high-dose users require regular cardiac ultrasound examinations

Monitoring for valvular regurgitation and risk of fibrosis

Side Effect Management :

Nausea and vomiting : Take after meals to relieve gastrointestinal reactions

Orthostatic hypotension : Change body position slowly and drink plenty of water

Impulse Control Disorders : Monitoring for Unusual Behavioral Changes

Why Cabergoline?

One of the most potent prolactin inhibitors , with significant effects

Long-lasting properties , reducing dosing frequency and improving convenience

Highly tolerable , with significantly fewer side effects than bromocriptine

Quality Assurance :

GMP compliant production , content uniformity testing for each batch

Third-party laboratory report (COA) is included with the product

Aluminum foil blister packaging to ensure stability

Worldwide Shipping :

100 tablets/bottle economical pack to meet treatment needs

Original sealed packaging , private delivery

Temperature -controlled transportation to ensure drug efficacy

Conclusion

Cabergoline is an ideal choice for the prevention of hyperprolactinemia and progestin side effects . It is particularly suitable for the treatment of hyperprolactinemia, the prevention of progestin-related side effects during steroid cycles, and the treatment of Parkinson's disease . The recommended dose is 0.25-1.0 mg/week .

Need a specific usage plan ?

We provide professional medication guidance to help you achieve your goals safely and efficiently!

Need anything, please contact us